| Previous close | 0.0900 |
| Open | 0.0800 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 330.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0800 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 528 |
- Reuters
UPDATE 5-Novo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before earnings on Thursday, on the back of Wegovy's popularity. Sales growth in the U.S. was positively impacted by a one-off sales adjustment, the company said.
ReutersNovo Nordisk raises 2024 outlook after profit beat fueled by obesity drug demand
LONDON (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before earnings on Thursday, on the back of Wegovy's popularity. Sales growth in the U.S. was positively impacted by a one-off sales adjustment, the company said.
- Reuters
FOCUS-British pharmacies vie for weight-loss patients with drug price cuts
Online pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just months after the weight-loss drugs were launched there, as initial supply shortages ease. But growing competition between retailers has raised fears that some patients who buy the drugs themselves, rather than relying on the National Health Service (NHS), will miss out on long-term aftercare if they keep switching providers.
